Avigen Report issue

For profit Phase 1 Phase 2
Founded: Alameda CA United States (1992)
Status: Acquired by MediciNova (2009)

Organization Overview

First Clinical Trial
2004
NCT00076557
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2007

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Avigen, Inc.

Active Ingredients

Drugs in Phase 2 Trials (3)

adeno-associated viral with human factor ix (1 trial)

ibudilast (1 trial)

tolperisone (4 trials)

Drugs in Phase 1 Trials (2)

fluvoxamine (luvox) (1 trial)

paroxetine (paxil) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetic Neuropathies (Phase 2)

Hemophilia A (Phase 2)

Hemophilia B (Phase 2)

Multiple Sclerosis (Phase 2)

Muscle Spasticity (Phase 2)

Neuralgia (Phase 2)

Sclerosis (Phase 2)

Spinal Cord Injuries (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 6
  • # of Trial APIs: 5